Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 18.00 |
|---|---|
| High | 18.40 |
| Low | 18.00 |
| Bid | 18.80 |
| Offer | 18.90 |
| Previous close | 17.30 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 88.20m |
| Free float | 85.32m |
| P/E (TTM) | -- |
| Market cap | 1.91bn USD |
| EPS (TTM) | -3.30 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 14:05 GMT.
More ▼
Announcements
- Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- Syndax Announces Participation in March Investor Conferences
- Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026
- Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference
- Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
- Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
- Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
- Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
More ▼
